Dabigatran antithrombotics

Pradax - Pradaxa      

pdf
pathology Demonstrated benefit and harm k      
acute coronary syndrome

versus placebo and control

No demonstrated result for efficacy

1 trialmeta-analysis
atrial fibrillation

versus anticoagulant

No demonstrated result for efficacy

dabigatran 150mg inferior to warfarin standard dose in terms of Gastrointestinal major bleeding in RE-LY (150mg), 2009

6 trialsmeta-analysis
post acute coronary syndromes

versus placebo and control

No demonstrated result for efficacy

1 trialmeta-analysis
post myocardial infarction

versus placebo and control

No demonstrated result for efficacy

1 trialmeta-analysis
thrombosis prevention

versus Low molecular weight heparin

No demonstrated result for efficacy

dabigatran 220mg inferior to enoxaparin (US regimen) in terms of total VTE and all-cause mortality in RE-MOBILIZE (220mg), 2008 (knee surgery patients)

dabigatran 150mg inferior to enoxaparin in terms of symptomatic DVT in RE-NOVATE (150mg), 2007 (hip surgery patients)

dabigatran 150mg inferior to enoxaparin (US regimen) in terms of distal DVT in RE-MOBILIZE (150mg), 2008 (knee surgery patients)

dabigatran 150mg inferior to enoxaparin (US regimen) in terms of total VTE and all-cause mortality in RE-MOBILIZE (150mg), 2008 (knee surgery patients)

7 trialsmeta-analysis
venous thrombosis

versus warfarin

No demonstrated result for efficacy

1 trialmeta-analysis
venous thrombosis

versus discontinuation

No demonstrated result for efficacy

1 trialmeta-analysis
venous thrombosis

versus heparin/VKA

No demonstrated result for efficacy

2 trialsmeta-analysis